Study: Patients willing to incur risks for benefits of novel T1D therapies
A new Breakthrough T1D-funded study finds that people with T1D and their caregivers are largely willing to try advanced new T1D therapies.
A new Breakthrough T1D publication is paving the way for beta cell replacement therapies
Breakthrough T1D’s newest publication outlines a roadmap for beta cell replacement therapies for type 1 diabetes.
Advancing access, equity, and action in India and around the world
The Udaipur Type 1 Diabetes Summit gathered international leaders to develop a collaborative roadmap for strengthening T1D care across India.
“We are our own solution:” A T1D parent’s reflection on progress
Moira McCarthy reflects on the transformative impact of automated insulin delivery systems, and how the T1D community made it possible.
170 Delegates make their mark on Capitol Hill at Breakthrough T1D 2025 Children’s Congress
170 Delegates with type 1 diabetes traveled to Washington, D.C. for the Breakthrough T1D 2025 Children's Congress.
ADA 2025 Recap: Medical Affairs
Medical Affairs (+Research and Advocacy) Breakthrough T1D’s Medical Affairs program is bridging the gap between access to and adoption of therapies, treatments, drugs, and devices for T1D. To accomplish this goal, the Medical Affairs team is working on healthcare provider (HCP) education, development of clinical care guidelines, and clinical trial education and awareness. Breakthrough T1D’s […]
Breakthrough T1D helps organize an event at the European Parliament about unmet needs for T1D and accelerating cures
This meeting focused on the role of the EU in addressing the needs of the T1D community and accelerating T1D breakthroughs.
The essential role of Advocacy in advancing T1D cell therapies
Breakthrough T1D's Advocacy efforts contribute to clear and efficient policies and secure government funding for manufactured cell therapies.
New Breakthrough T1D publications highlight unmet needs and demographics of the T1D population
Breakthrough T1D recently published two peer-reviewed journal articles. One detailed burdensome unmet needs in the T1D community and identified key steps we can take to meet these needs. The other used real-world data to better understand American T1D demographics and predict changes in the next decade.
Challenges and solutions: The present and future of cell therapies for T1D
Breakthrough T1D is funding research that supports manufactured islet cell source, survival, and protection and is also driving initiatives to unlock access to manufactured islet therapies for people with T1D.
